2026-04-17T03:37:38Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/95232024-12-13T09:40:10Zcom_2072_378070com_2072_378040col_2072_378092

2023-11-08T10:19:34Z urn:hdl:11351/9523 Expert opinion paper on the treatment of hemophilia A with emicizumab López Jaime, Francisco José Benítez Hidalgo, Olga Díaz Jordán, Bolívar Luis Montaño, Adrián Coll, Julia Quintana Paris, Laura Hemofília - Tractament Immunoglobulines - Ús terapèutic DISEASES::Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::Hemophilia A Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Bispecific Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::hemofilia A Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos biespecíficos Otros calificadores::Otros calificadores::/uso terapéutico Hemophilia A; Inhibitor; Joint health Hemofília A; Inhibidor; Salut articular Hemofilia A; Inhibidor; Salud articular Introduction Prophylaxis with emicizumab, a bispecific monoclonal antibody that mimics FVIII function, has shown encouraging results in clinical trials in terms of efficacy and safety. However, current experience is limited, and many areas of concern to clinicians have yet to be reviewed. Areas covered This paper reviews the experience of hemophilia A patients treated with emicizumab based on the results of clinical trials and real-life studies. The authors place special emphasis on issues such as the management of these patients in situations of hemorrhage and/or surgical interventions, joint health or laboratory monitoring. Expert opinion Treatment with emicizumab has been shown to improve joint health and reduce bleeding, of particular interest to patients with inhibitors and high bleeding rates. However, there are still concerns about its administration in neonates and previously untreated patients due to limited reported experience. Laboratory monitoring is not strictly necessary due to the stable pharmacokinetics emicizumab has been shown to exhibit, however, tests that globally assess hemostasis may be useful especially in cases of bleeding or surgery. The authors are also of the opinion that prophylaxis before minor surgery is not necessary and that major surgeries can be safely performed with additional prophylactic coagulation factor. This work was supported by European Union – Next Generation EU through a Margarita Salas contract of the University of Salamanca. 2023-11-08T10:19:34Z 2023-11-08T10:19:34Z 2023-05-12T11:21:26Z 2023-05-12T11:21:26Z 2023 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/9523 Hematology;28(1) https://doi.org/10.1080/16078454.2023.2166334 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Taylor & Francis Scientia